Mankind Pharma is expanding its presence in India’s insulin market as it broadens its diabetes-care portfolio. The company is focusing on strengthening its position in chronic therapies, where rising diabetes prevalence is supporting long-term demand.
The expansion comes as pharmaceutical companies increasingly target specialised and high-growth therapeutic segments. Mankind’s management has also maintained its profitability guidance, with the company continuing to focus on improving margins and expanding its product portfolio.
